Although Hand-Foot Syndrome (HFS) is not life threatening, it can cause a significant discomfort and impairment of function. Especially in elderly patients, this may have a major impact on quality of life (QoL) and to maintain treatment. There are effective measures for the prevention and treatment of HFS such as systemic and local treatment, dose reductions and switching to other drugs in the same class with a lower incidence of HFS. This approach allows patients to continue their treatment while reducing the negative impact on QoL.
At the request of the authors, Meducom assisted in the development of a recently published peer-review paper on the management of chemotherapy-induced HFS by compiling the available data in order to come to a comprehensive overview with clear advice for daily practice. It is the hope of the authors that the paper will be helpful to all those involved in the management of HFS and will ultimately benefit the patients.
J.J.M. Kwakman et al. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncology Reviews 2020; volume 14: 442